Since discovering adiponectin in the 1990 s, it has become a widely accepted biomarker for obesity-related diseases such as metabolic syndrome, Type 2 Diabetes mellitus, and atherosclerotic cardiovascular disease and its anti-inflammatory properties are well-documented as well [42–45]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.